Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study

Coronel-Martinez, DL; Park, J; Lopez-Medina, E; Capeding, MR; Bonfanti, AAC; Montalban, MC; Ramirez, I; Gonzales, MLA; DiazGranados, CA; Zambrano, B; Dayan, G; Savarino, S; Chen, ZH; Wang, H; Sun, S; Bonaparte, M; Rojas, A; Ramirez, JC; Verdan, MA; Noriega, F

Coronel-Martinez, DL (corresponding author), Sanofi Pasteur, Ciudad De Mexico 04000, Mexico.

LANCET INFECTIOUS DISEASES, 2021; 21 (4): 517

Abstract

Background Three doses of the licensed tetravalent dengue vaccine CYD-TDV (Dengvaxia, Sanofi Pasteur, Lyon France) are immunogenic and effective again......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索